The eye allergy treatment market size is expected to grow from US$ 3.59 billion in 2022 to US$ 5.69 billion by 2030; it is projected to register a CAGR of 5.9% during 2022-2030.

Eye allergy treatment includes products and solutions that are used to treat and manage allergies affecting the eyes. Treatment includes over-the-counter medications and prescription drugs used to improve symptoms such as redness, itching, tearing, and swelling of the eyes. The eye allergy treatment market growth is attributed to the increasing prevalence of eye allergies worldwide and a significant number of switches from prescription to over-the-counter drugs. However, a lack of awareness of ocular allergies and side effects associated with medications hinders the growth of the eye allergy treatment market.

Various measures and efforts have recently been taken to create awareness and educate people regarding eye diseases, prompting patients to access suitable medications and treatments for such conditions. A large population in India resides in rural areas with limited or no awareness of eye ailments. Sightsavers-an international nongovernmental organization-works in developing countries to treat and prevent eye diseases with an aim to create awareness with its Rural Eye Health Programme, provide high-quality eye health services, and eradicate avoidable blindness in the rural population. In addition, the World Health Organization (WHO) launched the Universal Health Coverage and Eye Care: Promoting Country Action, an event to provide practical, step-by-step guidance to support Member States of WHO in planning and implementing the WHO's World Report on Vision recommendations. Thus, such initiatives are likely to offer new opportunities for the growth of the eye allergy treatment market.

Treatment-Based Insights

Based on treatment, the eye allergy treatment market is categorized into medication, allergy shots, and eye drops. The eye drops segment held a significant eye allergy treatment market share in 2022. The segment is estimated to register the highest CAGR during the forecast period. Doctors generally prescribe eye drops for the treatment and prevention of eye allergies and diseases. Rising levels of air pollution, including dust, pollen, and other allergens, influence the growing incidences of eye allergies among people. Eye drops are used to prevent and cure itchy eyes caused by allergies. Dr Reddy's Laboratories launched Olopatadine Hydrochloride Ophthalmic Solution, an over-the-counter eye allergy drop in September 2020, in the US market, which is positively influencing the eye allergy treatment market growth.

Indication-Based Insights

Based on indication, the eye allergy treatment market is categorized into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, contact allergic conjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis. The seasonal and perennial allergic conjunctivitis segment held a significant eye allergy treatment market share in 2022 and is projected to register the highest CAGR during 2022-2030. Eye allergies develop when the immune system gets sensitized and overreacts to something in the surroundings that would normally cause no problems in most people. An allergic reaction can occur when an allergen comes in contact with antibodies associated with the mast cells in the eyes; the cells release histamine and other constituents or chemicals, causing tiny blood vessels to leak and the eyes to become itchy, red, and watery. Eye allergies share symptoms with several eye diseases, making precise diagnosis and detection imperative. Seasonal allergic conjunctivitis and perennial allergic conjunctivitis are the most common forms of eye allergies. Signs and symptoms of both conditions are the same. The difference is the specific allergens to which the patient is allergic. Airborne pollens usually cause seasonal allergic conjunctivitis. Its symptoms usually occur in the spring and summer and generally abate during winter. Perennial allergic conjunctivitis can occur throughout the year with exposure to perennial allergens, such as mold, dust mites, pet dander, or other household allergens. Diagnostic features of both allergic conjunctivitis consist of itching, redness, and swelling of the conjunctiva.

Seasonal allergic conjunctivitis can be treated with antihistamines, anti-inflammatory drugs, and mast cell inhibitors. For perennial allergic conjunctivitis, antihistamines are usually prescribed, but only temporarily because they worsen the symptoms of dryness. Steroids and mast cell inhibitors may also be used. These medications are usually required for the whole year around.

The US Food and Drug Administration, the World Health Organization, and the National Health and Wellness Survey are among the primary and secondary sources referred to while preparing the eye allergy treatment market report.